Creatine for women in pregnancy for neuroprotection of the fetus
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Creatine is an amino acid derivative and, when phosphorylated (phosphocreatine), is involved in replenishing adenosine triphosphate (ATP) via the creatine kinase reaction. Cells obtain creatine from a diet rich in fish, meat, or dairy and by endogenous synthesis from the amino acids arginine, glycine, and methionine in an approximate 50:50 ratio. Animal studies have shown that creatine may provide fetal neuroprotection when given to the mother through her diet in pregnancy. It is important to assess whether maternally administered creatine in human pregnancy (at times of known, suspected, or potential fetal compromise) may offer neuroprotection to the fetus and may accordingly reduce the risk of adverse neurodevelopmental outcomes, such as cerebral palsy and associated impairments and disabilities arising from fetal brain injury. OBJECTIVES: To assess the effects of creatine when used for neuroprotection of the fetus. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 November 2014). SELECTION CRITERIA: We planned to include all published, unpublished, and ongoing randomised trials and quasi-randomised trials. We planned to include studies reported as abstracts only as well as full-text manuscripts. Trials using a cross-over or cluster-randomised design were not eligible for inclusion.We planned to include trials comparing creatine given to women in pregnancy for fetal neuroprotection (regardless of the route, timing, dose, or duration of administration) with placebo, no treatment, or with an alternative agent aimed at providing fetal neuroprotection. We also planned to include comparisons of different regimens for administration of creatine. DATA COLLECTION AND ANALYSIS: We identified no completed or ongoing randomised controlled trials. MAIN RESULTS: We found no randomised controlled trials for inclusion in this review. AUTHORS' CONCLUSIONS: As we did not identify any randomised controlled trials for inclusion in this review, we are unable to comment on implications for practice. Although evidence from animal studies has supported a fetal neuroprotective role for creatine when administered to the mother during pregnancy, no trials assessing creatine in pregnant women for fetal neuroprotection have been published to date. If creatine is established as safe for the mother and her fetus, research efforts should first be directed towards randomised trials comparing creatine with either no intervention (ideally using a placebo), or with alternative agents aimed at providing fetal neuroprotection (including magnesium sulphate for the very preterm infant). If appropriate, these trials should then be followed by studies comparing different creatine regimens (dosage and duration of exposure). Such trials should be high quality and adequately powered to evaluate maternal and infant short and longer-term outcomes (including neurodevelopmental disabilities such as cerebral palsy), and should consider utilisation/costs of health care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Prognostic Messages from a Systematic Review on Cerebral Palsy
Novak, I., Hines, M., Goldsmith, S., & Barclay, R. (2012) · Pediatrics · doi:10.1542/peds.2012-0924 · Cited by 608
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448
Sestili, P., Martinelli, C., Bravi, G., Piccoli, G., Curci, R., Battistelli, M., Falcieri, E., Agostini, D., Gioacchini, A. M., & Stocchi, V. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.035 · Cited by 220
Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice
Zhu, S., Li, M., Figueroa, B. E., Liu, A., Stavrovskaya, I. G., Pasinelli, P., Beal, M. F., Brown, R. H., Kristal, B. S., Ferrante, R. J., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1278-04.2004 · Cited by 138
Improved Reperfusion and Neuroprotection by Creatine in a Mouse Model of Stroke
Prass, K., Royl, G., Lindauer, U., Freyer, D., Megow, D., Dirnagl, U., Stöckler-Ipsiroglu, G., Wallimann, T., & Priller, J. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600351 · Cited by 128
Melatonin Promotes Oligodendroglial Maturation of Injured White Matter in Neonatal Rats
Olivier, P., Fontaine, R. H., Loron, G., Van Steenwinckel, J., Biran, V., Massonneau, V., Kaindl, A., Dalous, J., Charriaut-Marlangue, C., Aigrot, M.-S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007128 · Cited by 119
Sakellaris, G., Kotsiou, M., Tamiolaki, M., Kalostos, G., Tsapaki, E., Spanaki, M., Spilioti, M., Charissis, G., & Evangeliou, A. (2006) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/01.ta.0000230269.46108.d5 · Cited by 116
Adcock, K. H., Nedelcu, J., Loenneker, T., Martin, E., Wallimann, T., & Wagner, B. P. (2002) · Developmental Neuroscience · doi:10.1159/000069043 · Cited by 97
Gualano, B., de Salles Painelli, V., Roschel, H., Lugaresi, R., Dorea, E., Artioli, G. G., Lima, F. R., da Silva, M. E. R., Cunha, M. R., Seguro, A. C., et al. (2011) · European Journal of Applied Physiology · doi:10.1007/s00421-010-1676-3 · Cited by 88
Dickinson, H., Ellery, S., Ireland, Z., LaRosa, D., Snow, R., & Walker, D. W. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-150 · Cited by 74
Self-citation
Cited by
Touitou, Y., Touitou, D., & Reinberg, A. (2016) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2017.05.001 · Cited by 290
The complex aetiology of cerebral palsy
Korzeniewski, S. J., Slaughter, J., Lenski, M., Haak, P., & Paneth, N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0043-6 · Cited by 264
Minich, D. M., Henning, M., Darley, C., Fahoum, M., Schuler, C. B., & Frame, J. (2022) · Nutrients · doi:10.3390/nu14193934 · Cited by 176
Groom, K. M., & David, A. L. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.11.565 · Cited by 170
Dickinson, H., Ellery, S., Ireland, Z., LaRosa, D., Snow, R., & Walker, D. W. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-150 · Cited by 74
“The absence of any clinical trial at the present time of creatine supplementation in human pregnancy is an obvious barrier to the implementation of this treatment, although a trial of creatine for neuroprotection of the human fetus at term has recently been proposed [127].”
BackgroundSelf-citationEllery, S. J., LaRosa, D. A., Kett, M. M., Della Gatta, P. A., Snow, R. J., Walker, D. W., & Dickinson, H. (2016) · Amino Acids · doi:10.1007/s00726-015-2150-7 · Cited by 25
Self-citationEllery, S. J., Dickinson, H., McKenzie, M., & Walker, D. W. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2015.11.002 · Cited by 23
“Collectively, this is the basis for a recommendation for human trials of creatine in pregnancy (Dickinson et al., 2014a).”
Self-citationde Guingand, D. L., Palmer, K. R., Bilardi, J. E., & Ellery, S. J. (2020) · Midwifery · doi:10.1016/j.midw.2019.102599 · Cited by 15
Metadata
- Authors
- Dickinson, H., Bain, E., Wilkinson, D., Middleton, P., Crowther, C. A., & Walker, D. W.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-12-19
- Volume
- 2014
- Issue
- 12
- Pages
- CD010527-CD010527
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1552681600
- Cited by
- 72
- References
- 13
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.